MedTrace Logo

Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles

NCT00627406 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 384

Last updated 2013-11-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to possibly further improve the clinical outcome and explore the incidence of OHSS in patients, who have final oocyte maturation with GnRHa (Buserelin) in GnRH antagonist IVF/ICSI cycles

Conditions

  • OHSS (Ovarian Hyperstimulation)

Interventions

DRUG

Buserelin and Pregnyl

Subcutaneous injection 0.5 mg and 1500 IU

DRUG

Pregnyl

Subcutaneous injection 5000 IU

DRUG

Buserelin and Pregnyl

Subcutaneous injection 0,5 mg and 1500 IU + 1500 IU after 7 days

DRUG

Pregnyl

Subcutaneous injection 5000 IU

Sponsors & Collaborators

  • Regionshospitalet Viborg, Skive

    lead OTHER

Principal Investigators

  • Peter S Humaidan, MD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00627406 on ClinicalTrials.gov